Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom

trialsTrialRecruiting

Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom

A phase 1/2 trial of SHR-8068 in renal cell carcinoma, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.

Overview Connected3

Overview

Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom is a phase 1/2 interventional study registered as NCT07239596 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 92 participants planned, started 2026-01-06 and due to reach its primary completion in 2030-12. Interventions recorded: SHR-8068；Adebrelimab ；Bevacizumab, SHR-8068 ; SHR-4610. Conditions listed: Advanced Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.

Setting

An Open, Multicenter Phase Ib/II Clinical Study of SHR-8068 in Combination Anti-tumor Drugs for the Treatment of Advanced Renal Cell Carcinoma

Phase

Phase 1/2

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Registry

Started

2026-01-06

Enrolled

92 enrolled

Connected

Similar pages

Trial
A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Trial
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Trial
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Trial
A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Trial
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Trial
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Trial
A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Trial
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.

cancers

Renal cell carcinoma

drugs

Phase 3monoclonal antibody (anti-CTLA-4, per the sponsor's pipeline page; form not stated in the registry record)

companies

Jiangsu Hengrui Pharmaceuticals

Evidence strength18/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1/2+8
92 enrolled+10
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-16 · Jude Gomila · Header signup, trial wave 5 and Ask weighting · diff · file

Sources & links

ClinicalTrials.gov NCT07239596

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Renal cell carcinoma

Products

SHR-8068

Companies

Jiangsu Hengrui Pharmaceuticals

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct07239596/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct07239596.

WebMCP tools registered on this page: onco_search, onco_get_entity.